Parameters | No. of patients | LC | PFS | OS | |||
---|---|---|---|---|---|---|---|
2-year rate (%) | p | 2-year rate (%) | p | 2-year rate (%) | p | ||
Age (year) | |||||||
<53 | 20 | 95.0 | 0.782 | 80.0 | 0.634 | 95.0 | 0.776 |
≥53 | 20 | 94.7 | 70.0 | 95.0 | |||
Gender | |||||||
Male | 29 | 100.0 | 0.016 | 72.4 | 0.868 | 96.6 | 0.644 |
Female | 11 | 81.8 | 81.8 | 90.9 | |||
Histology | |||||||
Squamous cell carcinoma | 8 | 87.5 | 0.685 | 75.0 | 0.863 | 87.5 | 0.212 |
Non-keratinizing carcinoma | 32 | 96.8 | 75.0 | 96.9 | |||
T stage | |||||||
3 | 26 | 96.2 | 0.276 | 73.1 | 0.592 | 96.2 | 0.721 |
4 | 14 | 92.3 | 78.6 | 92.9 | |||
N stage | |||||||
0-2 | 31 | 93.4 | 0.239 | 77.4 | 0.811 | 93.5 | 0.734 |
3 | 9 | 100.0 | 66.7 | 100.0 | |||
Treatment modality | |||||||
Chemo + RT | 21 | 95.0 | 0.086 | 76.2 | 0.594 | 95.2 | 0.968 |
Chemo + CCRT | 19 | 94.7 | 73.7 | 94.7 | |||
HI-T | |||||||
<2.9 | 23 | 100.0 | 0.028 | 100.0 | <0.0001 | 100.0 | 0.022 |
≥2.9 | 17 | 87.8 | 41.2 | 88.2 | |||
SUVmax-T | |||||||
<15.6 | 29 | 100.0 | 0.001 | 72.4 | 0.933 | 96.6 | 0.641 |
≥15.6 | 11 | 81.8 | 81.8 | 90.9 | |||
SUVmean-T | |||||||
<4.7 | 23 | 100.0 | 0.006 | 69.6 | 0.929 | 95.7 | 0.942 |
≥4.7 | 17 | 88.2 | 82.4 | 94.1 | |||
MTV-T (ml) | |||||||
<28.9 | 13 | 100.0 | 0.111 | 76.9 | 0.684 | 100.0 | 0.848 |
≥28.9 | 27 | 92.4 | 74.1 | 92.6 | |||
TLG-T (g) | |||||||
<249.1 | 27 | 100.0 | 0.006 | 74.1 | 0.976 | 96.3 | 0.898 |
≥249.1 | 13 | 84.6 | 76.9 | 92.3 | |||
HI-N | |||||||
<2.3 | 26 | 92.3 | 0.500 | 84.6 | 0.009 | 96.2 | 0.411 |
≥2.3 | 14 | 100.0 | 57.1 | 92.9 | |||
SUVmax-N | |||||||
<7.6 | 20 | 95.0 | 0.692 | 75.0 | 0.672 | 95.0 | 0.891 |
≥7.6 | 20 | 94.7 | 75.0 | 95.0 | |||
SUVmean-N | |||||||
<5.4 | 30 | 93.3 | 0.232 | 76.7 | 0.634 | 96.7 | 0.088 |
≥5.4 | 10 | 100.0 | 70.0 | 90.0 | |||
MTV-N (ml) | |||||||
<11.1 | 28 | 92.9 | 0.125 | 78.6 | 0.907 | 96.4 | 0.270 |
≥11.1 | 12 | 100.0 | 66.7 | 91.7 | |||
TLG-N (g) | |||||||
<80.4 | 32 | 93.6 | 0.235 | 75.0 | 0.429 | 93.8 | 0.770 |
≥80.4 | 8 | 100.0 | 75.0 | 100.0 |